METABOLIC & WEIGHT RESEARCH / MATRIX
Three Peptides, Three Layers of Metabolic Signaling
How a receptor agonist, a hormone fragment, and a mitochondria-encoded peptide differ in mechanism, evidence stage, and what each is actually studied for.
The short version
This page lines up semaglutide, AOD-9604, and MOTS-c on the dimensions that matter most when reading metabolic-peptide research: mechanism layer, evidence stage, regulatory status, and the single biggest caution for each. The headline is not subtle. These three compounds are not interchangeable, and they are not even at comparable stages of development — semaglutide is an approved medicine with a decade-plus, multi-thousand-patient trial record; AOD-9604 completed human testing and did not clear its own efficacy bar; MOTS-c has not yet reached a human efficacy trial at all. Reading them side by side is the fastest way to see how differently 'a metabolic research peptide' can be positioned. None of this is medical advice, and no dose is recommended here for any compound.
The comparison matrix
| Dimension | Semaglutide | AOD-9604 | MOTS-c |
|---|---|---|---|
| Mechanism layer | GLP-1 receptor agonist (incretin mimetic) | Growth-hormone C-terminal fragment (receptor-independent) | Mitochondria-encoded peptide (AMPK / CK2 pathway) |
| Most-studied in | Type 2 diabetes, obesity, cardiovascular and kidney outcomes | Obesity (Phase IIb, discontinued); preclinical joint models | Metabolic stress, exercise physiology, aging (preclinical) |
| Evidence base | Large RCTs: STEP, SELECT, FLOW programs; FDA-approved [4][3][2] | ~6 human trials (~900 subjects), safety only; no efficacy signal [8] | Mouse/rat studies plus a human observational cohort; no human RCT [12][16] |
| Regulatory status | FDA-approved (multiple indications) | Not approved; development discontinued | Not approved; sold as research chemical only |
| Anti-doping status | Not currently WADA-prohibited | WADA-prohibited (growth-hormone fragment, Section S2) | Treated as prohibited by anti-doping authorities |
| Key caution | GI intolerance; boxed thyroid warning; chronic-therapy framing [5] | Human obesity trial did not beat placebo; animal data did not translate [8][9] | No human efficacy trial; no established human pharmacokinetics [12][16] |
Mechanism layer
The three compounds work at genuinely different levels of biology, which is part of why comparing them is useful. Semaglutide engages a specific cell-surface receptor — GLP-1R — the same way the body's own after-meal hormone does, triggering a well-characterized cascade of insulin release, appetite suppression, and slowed digestion [4]. AOD-9604 does not engage a receptor system at all in the conventional sense; it was built to isolate a single downstream activity — fat metabolism — out of a much larger hormone, growth hormone, while deliberately avoiding growth hormone's own receptor [9]. MOTS-c works from a different starting point entirely: it is generated inside the mitochondrion, and its primary mechanism — inhibiting the folate cycle to activate AMPK, plus a newly identified direct interaction with the enzyme CK2 — does not involve a conventional cell-surface receptor either [11][16]. Three different entry points into the same broad goal: better management of appetite, blood sugar, and energy.
Evidence base
This is where the three genuinely diverge. Semaglutide's evidence base is the deepest of any compound on this desk: multiple multi-thousand-participant randomized trials across several indications, years of post-marketing safety surveillance, and a dedicated safety-review literature [2][3][4][5]. AOD-9604's evidence base is real but bounded — roughly six completed human trials totaling about 900 participants established that it is safe and well tolerated, but its own pivotal efficacy trial did not separate from placebo, and the program was discontinued as a result [8]. MOTS-c's evidence base is the earliest-stage of the three: everything published about its metabolic effects in a living organism comes from mouse and rat studies, and the human data that exist are an observational cohort linking naturally circulating levels to outcomes rather than a trial of giving the peptide to people [12][16]. Evidence stage, not mechanism alone, is the single most important thing to hold in mind when reading claims about any of these three.
Regulatory and anti-doping status
Semaglutide is an FDA-approved prescription medicine, available only through a licensed prescriber, with approvals spanning type 2 diabetes, chronic weight management, cardiovascular risk reduction, and metabolic liver disease. AOD-9604 was reviewed for a possible anti-obesity approval and never received one; its development program was discontinued after its pivotal trial, and as a growth-hormone-derived fragment it is separately classified as prohibited in elite sport under anti-doping rules covering peptide hormones and growth factors. MOTS-c is not approved for any human use anywhere and is sold, where it is sold, strictly as a laboratory research chemical; anti-doping authorities also treat mitochondrial-derived and metabolic-modulator peptides as prohibited substances, with sanctions for athletes who use them. None of the three is legally available for self-directed human use outside their respective regulatory lanes.
Key caution
Each compound carries a defining caveat worth holding onto. For semaglutide, it is that gastrointestinal intolerance dominates the adverse-effect picture during dose escalation, and that stopping the drug is followed by substantial weight regain in trial-extension data — this is chronic therapy, not a finite course [5]. For AOD-9604, it is that promising, mechanistically coherent rodent data simply did not survive contact with a well-designed human efficacy trial — a caution that applies to reading any early-stage metabolic-peptide research, not just this one compound [8][9]. For MOTS-c, it is that no human efficacy trial exists yet at all: what looks compelling in mice — improved insulin sensitivity, protection from diet-induced obesity, better physical performance in old age — has not been tested in people, and there is no established human dose-response relationship to reason from [12][16]. Reading the three side by side, the throughline is less about which peptide 'works' and more about how far each one's evidence actually reaches.